Controversial Advertising of Medicines : a Comparison between Poland and the United States

• Autorzy: Marta Makowska
• Języki publikacji: EN

Abstrakty

EN

For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical companies has been raised in Poland. Drug ads are everywhere, on television, the radio, magazines and on the Internet. Therefore, it is extremely important is to ensure both their legal and ethical dimension. This article will present the differences between direct-to-consumer advertising of medicines in Poland and in the US. The dissimilarities result mainly from differences in legislation. In Poland, the law is much stricter than in the US. For example, in the United States companies are allowed to advertise prescription drugs directly to patients. In the whole of the European Union, and thus in Poland, it is strictly prohibited. The article will also present other regulations existing in Poland and in the United States and it will compare them. It will offer examples of violations of the law and ethics in the advertising of medicine in both countries. Lastly, it will briefly outline the negative consequences of unacceptable pharmaceutical marketing. (original abstract)

Słowa kluczowe

EN

Pharmaceutical industry; Pharmaceutical law; Advertising; Ethics

PL

Przemysł farmaceutyczny; Prawo farmaceutyczne; Reklama; Etyka

• Czasopismo: Annales : etyka w życiu gospodarczym
• Rocznik: 2018
• Tom: 21
• Numer: nr 5
• Strony: 67--79

Twórcy

autor

Marta Makowska

• Warsaw University of Life Sciences

Bibliografia

• Arnold, D., & Oakley, J. (2013). The politics and strategy of industry self-regulation: The pharmaceutical industry's principles for ethical Direct-to-Consumer advertising as a deceptive blocking strategy. Journal of Health Politics, Policy and Law, 38(3), 505-544.
• ASRC. (2012). NARB Panel Recommends Novartis Discontinue Claims that Ex-cedrin Starts Relieving Headache Pain Faster than Advil Claims at Issue Challenged by Pfizer Consumer Healthcare. http://www.asrcreviews.org/ 2012/01/narb-panel-recommends-novartis-discontinue-claims-that-excedrin -starts-relieving-headache-pain-faster-than-advil-claims-at-issue-challenged-by-pfizer-consumer-healthcare/
• Blinkoff, S., & Tabela, K. (2015). USA - pharmaceutical advertising 2015. Inter-national comparative legal guides. http://www.iclg.co.uk/practice-areas/ pharmaceutical-advertising/pharmaceutical-advertising-2015/usa
• Chaniecka, K. A., & Czerw, A. (2013). Płeć a postrzeganie reklamy telewizyjnej leków OTC. Hygeia Public Health, 48, 509-514.
• Chief Pharmaceutical Inspectorate. (2011, January 31). Decision of 31.01.2011, sign: GIF-P-R-450/106-4/JD/10/11. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/80,Rok-2011.html
• Chief Pharmaceutical Inspectorate. (2012, April 26). Decision of 26.04.2012, sign: GIF-P-R-450/14-2/JD/12,2012. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/79,Rok-2012.html
• Chief Pharmaceutical Inspectorate. (2014, September 9). Decision of 11.09.2014, sign: GIF-P-R-450/46-2/JD/14. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje/619,Decyzja-z-dnia-11092014-znak-GIF-P-R-450 46-2JD14.html.
• Chief Pharmaceutical Inspectorate. (n.d.) Decisions and messages. https://www. gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje
• Committee of Advertising Ethics [Rada Reklamy]. (2011). Uchwała Nr ZO 40/11 w sprawie reklamy firmy Novartis Poland Sp. z o.o. [Resolution No. ZO 40/11 regarding the advertising of Novartis Poland Sp. z o.o.]. https://www.radareklamy.pl/uchwaly-ker/2011/uchwaÅ‚a-nr-zo-40-11-w-sprawie-reklamy-firmy-novartis-poland-sp-z-o-o
• Committee of Advertising Ethics [Rada Reklamy]. (2014). Uchwała Nr ZO 64/14 w sprawie reklamy firmy Pfizer Trading Polska Sp. z o.o. [Resolution No. ZO 64/14 regarding the advertising of Pfizer Trading Polska Sp. z o.o.]. https://www.radareklamy.pl/uchwaly-ker/2014/uchwaÅ‚a-nr-zo-64-14-w-sprawie-reklamy-firmy-pfizer-trading-polska-sp-z-o-o
• Committee of Advertising Ethics [Rada Reklamy]. Commission of Ethics [Komis-ja Etyki Reklamy]. https://www.radareklamy.pl/komisja-etyki-reklamy
• Consumer Healthcare Products Association. (2015). OTC Drug Advertising. http://www.chpa.org/OTCDrugAdvertising.aspx
• Diehl, S., Mueller, B., & Terlutter, R. (2008). Consumer responses towards non-prescription and prescription drug advertising in the US and Germany: They don't really like it, but they do believe it. International Journal of Advertising, 27(1), 99-131.
• Donohue, J. (2006). A history of drug advertising: The evolving roles of consumers and consumer protection. Milbank Quarterly, 84, 659-699.
• Faerber, A. E., & Kreling, D. H. (2012). Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Journal of General Internal Medicine, 29(1), 110-118.
• Food and Drugs Administration. (2014a). Cipher Pharmaceuticals Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeof ViolationLetterstoPharmaceuticalCompanies/UCM415228.pdf
• Food and Drugs Administration. (2014b). Pacira Pharmaceuticals, Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM416514.pdf
• Food and Drugs Administration. (2015a). Drug Applications for Over-the-Counter (OTC) Drugs. https://www.fda.gov/drugs/developmentapprovaprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counter drugs/default.htm
• Food and Drugs Administration. (2015b). Inspections, Compliance, Enforcement, and Criminal Investigations, Warrning Letters, Drugs. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActiviti- esbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCo-mpanies/default.htm
• Food and Drugs Administration. (n.d.). Prescription Drug Advertising. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/default.htm
• Frosch, D., Kruger, P. M., Hornik, R. C., Cronholm, P., & Barg, F. (2007). Creating demand for prescription drugs: A content analysis of television Direct-to-Consumer advertising. Annals of Family Medicine, 1(5), 6-13.
• Journal of Laws of the Republic of Poland 1991, No. 105, position 452. Act on pharmaceuticals, medical materials, pharmacies, wholesalers and pharmaceutical supervision. [Dz.U. 1991, No. 105, item 452, Ustawa o środkach farmaceutycznych, materiałach medycznych, aptekach, hurtowniach i nadzorze farmaceutycznym].
• Journal of Laws of the Republic of Poland 1993, No. 47, position 211. The Act on Combating Unfair Competition. [Dz.U. 1993, No. 47, item 211, Ustawa o zwalczaniu nieuczciwej konkurencji].
• Journal of Laws of the Republic of Poland 2008, No. 45, position 271. Pharmaceutical Law. [Dz.U. 2008, No. 45, item 271, Prawo Farmaceutyczne].
• Koncerny farmaceutyczne mocno inwestują w reklamę. Aflofarm na czele peletonu. (2014). www.marketingprzykawie.pl. http://www.marketing-news.pl/theme.php?art=1804.
• KPMG & IAA. (2015). Rynek reklamy telewizyjnej w Polsce po latach wychodzi na prostą. Warsaw.
• Kravitz, R. L. (2000). Direct-to-Consumer advertising of prescription drugs. Western Journal of Medicine, 173(4), 221-222.
• Kula, P. (2015). Pharmaexpert podsumowuje rynek apteczny w 2014 roku. http://www.aptekarzpolski.pl/2015/02/01-2015-pharmaexpert-podsumowuje-rynek-apteczny-w-roku-2014/
• Mack, J. (2015). Increased DTC advertising and rising drug prices - Is there a causal link? http://pharmamkting.blogspot.com/2015/11/increased-dtc-advertising-and-rising.html
• Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.
• Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.
• Michalski, B., Sławatyniec, Ł., Duczyńska, M., & Kęska, K. (2013). Prawo farmaceutyczne i refundacja leków. Warszawa: Wolters Kluwer.
• Mogull, S. A. (2008). Chronology of Direct-to-Customer advertising regulation in the United States. American Medical Writers Association Journal, 23(3), 106-109.
• PAIiIZ. (2013). Sektor faramaceutyczny i biotechnologiczny w Polsce. Warszawa: The Polish Investment and Trade Agency.
• Stange, K. C. (2007). Time to ban Direct-to-Consumer prescription drug marketing. Annals of Family Medicine, 5(2), 101-104.
• Sudak, I. (2015, March 4). My, Polacy, lekomani. Rekordowe wydatki na leki, groźne skutki reklam. Gazeta Wyborcza. http://wyborcza.biz/biznes/1,100896,17513743,My_Polacy_lekomani_Rekordowe_wydatki_na_leki_grozne.html

Identyfikatory

DOI

10.18778/1899-2226.21.5.06